Read More

Cyprium Therapeutics, A Fortress Biotech Subsidiary Company, Completes Asset Transfer Of CUTX-101 Copper Histidinate Product Candidate For Treatment Of Menkes Disease, To Sentynl Therapeutics, A Wholly-Owned Subsidiary Of Zydus Lifesciences Ltd.

Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership over any FDA

FBIO

Read More

Webuy Global Announces MOU To Acquire PT. Tiga Sakti Utama, A Leading Indonesian Fruit Importer And Wholesaler In Surabaya, Indonesia; Co Would Receive A 51% Equity Interest In TSU In Exchange For 800K Of The Co’s Shares With Certain Lockup Arrangement

Strategic acquisition intended to expand the company's foothold in Indonesia and SE AsiaTSU generated sales of approximately $15 million in 2022 with track record of profitabilitySingapore , Dec. 06, 2023 (GLOBE

WBUY